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1. Introduction
  Hepatocellular carcinoma (HCC) is one of the most 
common malignancies, with an increasing incidence 
all over the world. Traditional clinical treatments for 
hepatocellular carcinoma include surgery, chemotherapy 
and radiotherapy. And with advances in surgical techniques 
and instrumentation and the development of molecular-
target drugs, a number of potentially curative treatments 
have become available than ever before[1-3]. The therapeutic 
effect of liver resection was satisfied only in a small portion 
of patients with poor prognosis. Most HCC patients may 
have cirrhosis as well as hypersplenism and peripheral 
blood cells reduction in the meantime, so they may be 
unbearable for systemic chemotherapy while radiation 
therapy also works only for patients with good liver function 
without complications such as cirrhosis, ascites, jaundice, 
or any distant metastasis, which limits the application of the 
therapy methods[4-6].
  Recent years, with the development in molecular 
mechanisms about tumor cell growth, proliferation and 
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apoptosis, the molecular characteristics of tumors are 
better understood and it makes it possible for targeted 
cancer therapy that blocks the growth of cancer cells by 
interfering with specific targeted molecules or cytokines 
needed for carcinogenesis and tumor growth[7]. Increased 
understanding of the molecular mechanisms involved 
in cancer development has led to the identification of 
numerous novel targets for drug developments. Targeted 
therapy focus on certain specific signal transduction 
molecules including crucial molecules involved in cell 
proliferation and apoptosis, cell invasion, metastasis, cell-
cycle control, and tumor-related angiogenesis, and in recent 
years, antibody-drug conjugates have brought us into a new 
era for personalized cancer treatment which can improve the 
effects of anti-cancer drugs such as cytotoxic drugs while 
reducing their toxicity to normal organs[8,9].
  Tumor cells could produce angiogenic factor vascular 
endothelial growth factor (VEGF), which can bind vascular 
endothelial cell surface receptors, resulting in a variety of 
biological effects, thereby promoting tumor progression[10]. 
Arsenic trioxide (As2O3) has been used medicinally in 
traditional Chinese medicine for thousands of years, and it 
has been used for treatment of cancer for several hundred 
years of history, and its therapeutic use in leukaemia has 
been described a century before[11]. Until now, it has been 
reported to be used for the treatment of esophageal cancer, 
breast cancer, gastric carcinoma, colon cancer, cervical 
cancer, prostate cancer and other solid tumors[12-14]. But 
as a highly toxic drug, the application of arsenic trioxide is 
limited in clinical due to its poor targeting ability to tumor 
cells, which lead to great toxicity to normal cells of the 
body[11,15]. Our group previously have built anti-VEGFR-2 
ScFv modified As2O3-stealth nanoparticles (anti-VEGFR-2 
ScFv-As2O3-stealth nanoparticles) using molecular 
coupling technology to, in order to delivery As2O3 to targeted 
tumor cells. In this study, we investigated the inhibitory 
effect of humanized anti-VEGFR-2 ScFv-As2O3-stealth 
nanoparticles conjugate on growth of human hepatocellular 
carcinoma both in vitro and in vivo. 
2. Materials and methods
2.1. Cell culture and MTT assay
  The human hepatoma cancer cell line Bel7402 was 
purchased from the American Type Cell Culture (USA). 
Bel7402 cells were maintained in RPMI-1640 supplemented 
with 10% (v/v) heat-inactivated fetal bovine serum, 
penicillin-streptomycin (100 IU/mL-100 g/mL), 2 mM 
glutamine, and 10 mM Hepes buffer at 37 ℃ in a humid 
atmosphere (5%-95% CO2). The inhibitory effect of different 
drugs on Bel7402 cell proliferation was estimated by the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium 
bromide (MTT, Sigma-Aldrich, USA) assay[16].
2.2. Transwell assay
  Cell migration and invasion were assayed using a transwell 
chamber (Millipore, USA) with and without Matrigel (BD, 
Franklin Lakes, USA). For the invasion assay, a transwell 
chamber was placed into a 24-well plate and was coated 
with 30 毺L Matrigel and was incubated for forty minutes at 
37 曟. Cells were trypsinized and seeded in chambers at the 
density of 1伊106 cells per ml and cultured in medium with 
RPMI 1640 medium with 2% serum, while 500 毺L of 10% 
FBS-1640 was added to the lower chamber. Twenty-four 
hours later, migrated cells were fixed with 100% methanol for 
30 min. Non-migrated cells were removed by cotton swabs. 
Then cells on bottom surface of the membrane were stained 
by crystal violet for 20 min. Cell images were obtained under 
a phase-contrast microscope (Olympus, Tokyo, Japan)[17].
2.3. Hochest33258 staining morphological studies
  Variations in cell morphology were analyzed by 
fluorescence microscopy. Cells attached to coverslips were 
fixed in cold methanol for 5 min, air dried, stained with 
Hoechest-33258 (1 毺L Hochest 33258 in 100 毺L PBS) and 
observed under Olympus BX61 microscope.
2.4. DNA ladder analysis of DNA fragmentation
  Fragmentation of DNA was analyzed by agarose gel 
electrophoresis during apoptosis. Bel 7402 cells were treated 
with different drugs for 4 h, then irradiated for 10 min with 
uorescent light, and incubated for 4 h or overnight. DNA 
was extracted with phenol/chloroform and precipitated in 
ethanol. The extracted DNA was separated by agarose gel 
electrophoresis (1.5% agarose gel containing 0.4 毺g/mL
ethidium bromide, 100 V, 1 h) and visualized under UV 
light[18]. 
2.5. In vivo activity of humanized anti-VEGFR-2 ScFv-
As2O3-nanoparticles  
  Six-week-old male nude (nu/nu) BALB/c mice (SLRC 
Laboratory Animal, Shanghai, China) weighing 18-20 g were 
used for all experiments. Tumor models were established 
by a subcutaneous injection of 1伊107 Bel7402 cells into the 
back of mice. Tumor volumes were estimated according 
to the formula: 0.5伊ab2 (a, length; b, width). When tumors 
reached about 100 mm3, the mice were randomly assigned 
to five groups (8 mice per group): intravenous injection of 
anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles (group A, 
containing 5 mg/kg of equivalent As2O3), As2O3 nanoparticles 
(group B, containing 5 mg/kg of equivalent As2O3), anti- 
VEGFR-2 ScFv (group C, containing an identical antibody 
concentration as anti-VEGFR-2 ScFv-As2O3-nanoparticles 
injected), As2O3 solution (group D, 5 mg/kg) and saline (group 
E, received 0.2 mL ip. injections of saline). The drugs were 
administered once a day for 5 consecutive days. 
  Tumor volumes were measured every 2 d after termination 
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of drug administration. 12 days after drug administration, 
peripheral blood of the mice were collected to detect 
leukocytes [white blood count (WBC)] and platelets PLT) 
levels, then the mice were sacrificed, and tumors were 
excised and weighed.
2.6. Immunohistochemistry and microvascular density (MVD)
  After sacrifice, the tumor tissues were removed from 
each mouse. Some of the tumor tissues were subsequently 
fixed in formalin, embedded in paraffin and stained with 
hematoxylin and eosin (H&E) for further investigation.
  Angiogenesis in tumor tissues was evaluated according to 
MVD counting by staining with CD34. After deparaffinization 
and antigen retrieval, endogenous peroxidase was blocked. 
The sections were washed and non-specific binding was 
blocked and then sections were incubated with CD34 
primary antibody and then treated with biotinylated anti-
immunoglobulin.
2.7. TUNEL
  Apoptotic cells in tumor tissues were determined by 
terminal deoxynucleotidyl transferase-mediated dUTP nick 
end labeling (TUNEL) staining using an in situ cell death 
detection kit (Roche, Mannheim, Germany) using serial 4 毺m
sections cut from paraffin-embedded tumor tissues. The 
staining was performed according to the manufacturer’s 
instructions. The proportion of apoptotic cells in six mice 
was scored in randomly chosen fields under a microscope[19].
2.8. Western blot
  Western blotting was performed to examine the expression 
of apoptosis protein in tumor tissues and normal tissues. 
To prepare lysates of cancer tissue, about 10mg of each 
tumor tissue sample was incubated with 80 Ⅱ Radio 
Immunoprecipitation Assay lysis buffer at 4 ℃ for 30 min 
and the lysates (30 毺g of protein per lane) were fractionated 
by SDS-PAGE. The proteins were electro-transferred onto 
poly (vinylidene fluoride) (PVDF) membranes and were 
detected using dilutions of the primary antibodies. The 
primary antibodies included caspase-3, caspase-9 (Cell 
Signaling, Danverse, MA) and 毬-actin (Abcam, Cambridge, 
MA). The PVDF membranes were washed in 0.05% 
Tween-20/Tris-buffered saline and then incubated with 
horseradish peroxidase-conjugated secondary antibody. 
The bound antibodies were visualized using an enhanced 
chemiluminescence reagent (Millipore, Billerica, MA) and 
quantified by densitometry using ChemiDoc XRSþ image 
analyzer (Bio-Rad, Hercules, CA). Densitometric analyses of 
bands were adjusted with b-actin functioning as a loading 
control. All experiments were performed in triplicate.
2.9. Statistical analysis
  Statistical analysis was performed using SPSS/Win13.0 
software (SPSS, Inc., Chicago, Illinois, USA). Data are 
presented as means依SD and were analyzed by one-
way ANOVA. Multiple between-group comparisons were 
performed using the S-N-K method. A P value <0.05 was 
considered statistically significant. 
3. Results
3.1. Inhibitory effect of anti-VEGFR-2 ScFv-As2O3-stealth 
nanoparticles on hepatoma carcinoma cell growth and 
triggers cell apoptosis
  The inhibitory effect of anti-VEGFR-2 ScFv-As2O3-stealth 
nanoparticles and other parallel drugs on proliferation of 
hepatoma carcinoma cells was examined using Bel7402 
cell line. As shown in Figure 1a, the drugs had dose-
dependent anti-proliferative effects on Bel7402 cells (P< 
0.05 vs. untreated control). Although the highest inhibition 
rate of As2O3-stealth nanoparticles was a bit higher than 
anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles, the 
ID50 of anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles 
was smaller than As2O3-stealth nanoparticles. While anti-
VEGFR-2 ScFv-As2O3-stealth nanoparticles and anti-
VEGFR-2ScFv had almost no effects on normal liver cell 
line L02 (Figure 2B).
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Figure 1. Efffect of different drugs on cell proliferation.
(A) Inhibition of proliferation on Cel7402.
(B)Effects of drugs on normal liver cells L02.
A, Anti-VEGFR-2 ScFv-As2O3 stealth nanoparticles group; B, 
As2O3 stealth nanoparticles group; C. anti-VEGFR-2 ScFv; D, As2O3 
solution group.
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Figure 2. Cell apoptosis induced by different drugs.
(A) Hochest33258 staining detected the cellular morphology of 
Bel7402 treated by drugs; (B) DNA ladder test detected DNA 
fragmentation after treatment.
A. Anti-VEGFR-2 ScFv-As2O3 stealth nanoparticles group; B, 
As2O3 stealth nanoparticles group; C. anti-VEGFR-2 ScFv; D, As2O3 
solution group; E. saline (Control).
  Meanwhile, Hochest33258 staining showed that if the 
nuclei showed chromatin condensation, marginalization, 
or appeared beaded nuclear, the cell was in the process 
of apoptosis. Normal cells were observed to be dispersed 
fluorescence, circular or oval nucleus (Figure 2A). As shown 
in Figure 2, the chromatin condensation and marginalization 
condition of cells in anti-VEGFR-2ScFv-As2O3 stealth 
nanoparticle group was the most significant, indicating 
the strongest effect of triggering apoptosis of cancer cells, 
followed by As2O3 stealth nanoparticle group, As2O3 group, 
and anti-VEGFR-2ScFv group. The apoptosis inducing 
effects of different drugs was also confirmed by DNA ladder 
analysis (Figure 2B).
3.2. Inhibition of hepatoma carcinoma cell invasion and 
migration
  The inhibitory effect of drugs on invasion and migration of 
hepatoma carcinoma cells was examined using an invasion 
assay with Matrigel-coated filters. In the absence of drug 
treatment (control group), Bel7402 cells displayed high 
invasive capability as indicated by being able to completely 
penetrate through the Matrigel-coated filters (Figure 3E). 
The activity of invasion and migration of cancer cells was 
markedly suppressed by a 24-h exposure. 
  At concentrations of 100 ng/mL of anti-VEGFR-2 ScFv-
As2O3-stealth nanoparticles, As2O3-stealth nanoparticles, 
anti-VEGFR-2 ScFv, and As2O3, the number of cells able to 
penetrate through the Matrigel-coated filters was decreased 
by 65.4%, 50.6%, 56.5%, and 40.7%, respectively (P<0.01 vs. 
untreated control; Figure 3).
Figure 3. Invasive ability of cells detected using Transwell assay.
A. Anti-VEGFR-2 ScFv-As2O3 stealth nanoparticles group; B, 
As2O3 stealth nanoparticles group; C. anti-VEGFR-2 ScFv; D, As2O3 
solution group; E. saline (Control).
3.3. Anti-VEGFR-2 ScFv- As2O3 stealth nanoparticles 
antitumor activity in vivo
  Tumor volumes were measured every two days since the 
drug administration. Our results showed that the tumor 
volumes in treatment group were much more smaller 
compared with the control group (P<0.01, Figure 2A). Among 
them, the anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles 
treatment had the most strong inhibition effect on tumor 
growth (tumor weight and tumor volume were both the 
smallest, P<0.05, inhibition rate 92.9%), followed by anti-
VEGFR-2 ScFv and As2O3-stealth nanoparticles, and 
As2O3 (Figure 2B). The inhibition rates of the drugs were 
summarized in Table 1.
Table 1
Tumor weight and inhibition rate of each group.
Indexes A* B* C* D*
Tumor weight(g) 0.30依0.14 1.71依0.07 1.60依0.30 3.30依0.18
Inhibition rate(%) 92.9 58.89 61.4 20.5
A. Anti-VEGFR-2 ScFv-As2O3 stealth nanoparticles group; B. 
As2O3 stealth nanoparticles group; C. anti-VEGFR-2 ScFv; D. As2O3 
solution group; E. saline (control). Data were shown as Mean 依SD, *P 
<0.05 vs. control.
  Blood tests showed that platelet and white blood cell 
count in As2O3 group were significantly decreased (P<0.05 
vs. control), while in other groups we did not notice obvious 
effects on blood samples, indicating that the toxicity of the 
other groups were not so significant (Table 2).
  Meanwhile, we found through general observation that the 
Table 2
Results of blood test for PLT and WBC.
Indexes A B C D E
PLT(伊109/L) 101.3依23.4 102.3依12.9 104.4依19.0 63.3依14.1* 105.5依26.5
WBC(伊109/L)   7.5依1.7   7.7依1.5   7.8依2.0 3.9依0.9*   7.9依1.2
A. Anti-VEGFR-2 ScFv-As2O3 stealth nanoparticles group; B. As2O3 stealth nanoparticles group; C. anti-VEGFR-2 ScFv; D. As2O3 solution 
group; E. saline (control). Data were shown as Mean 依SD, *P<0.05 vs. control.
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activity of mice in the control group was reduced, and the 
weight of the mice were decreased with emaciated cachexia, 
while the health condition of mice in treatment group were 
improved with basically normal activities, and condition of 
mice in anti-VEGFR-2 ScFv- As2O3 group were significantly 
better compared with the other groups.
3.4. Inhibition of tumor growth in vivo
  Tumor volumes were measured every two days since the 
drug administration. Our results showed that the tumor 
volumes in treatment group were much smaller compared 
with the control group (P<0.01, Figure 4). Among them, the 
anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles treatment 
had the most strong inhibition effect on tumor growth 
(inhibition rate 92.9%, P<0.05), followed by anti-VEGFR-2 
ScFv and As2O3-stealth nanoparticles, and As2O3 (Figure 4, 
Table 1).
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Figure 4. Effect of grugs on tumor volumes in different group.
A. Anti-VEGFR-2 ScFv-As2O3 stealth nanoparticles group; B, 
As2O3 stealth nanoparticles group; C. anti-VEGFR-2 ScFv; D, As2O3 
solution group; E. saline (Control).
  Blood tests showed that platelet and white blood cell 
count in As2O3 group were significantly decreased (P<0.05 
vs. control), while in other groups we did not notice obvious 
effects on blood samples, indicating that the toxicity of the 
other groups were not so significant (Table 2).
  General observation found that the activity of mice in 
the control group was reduced, and the weight of the mice 
were decreased with emaciated cachexia, while the health 
condition of mice in treatment group were improved with 
basically normal activities, and condition of mice in anti-
VEGFR-2 ScFv-As2O3 group were significantly better 
compared with the other groups.
3.5. Pathological and immunohistochemical results and 
detection of apoptosis pathway of cells in tumor tissue
  Histopathologic examination further validated the 
inhibitory effect of anti-VEGFR-2 ScFv-As2O3 on the 
tumorigenesis and malignant progression of liver cancer. As 
shown in Figure 3A a-e, anti-VEGFR-2 ScFv-As2O3 stealth 
nanoparticles caused the most severe necrosis of the tumor 
tissue, and there was barely obvious necrosis in control 
group. Cell apoptosis in tumor tissue was then detected 
by TUNEL. Data analysis showed that, the percentages of 
TUNEL-positive cells in anti-VEGFR-2 ScFv-As2O3 stealth 
nanoparticles group, As2O3 stealth nanoparticles group, anti-
VEGFR-2 ScFvC, As2O3 solution group and control group 
were 49.6%, 43.7%, 38.2%, 35.8%, and 19.1%, respectively 
(P<0.05 vs. control).
  Western blotting found that the levels of caspase-3 
and caspase-9 were increased in drug treatment groups, 
indicating that the drugs might have triggered tumor cell 
apoptosis through the caspase-dependent pathway (Figure 
5). While in the meantime, although the caspase-3,-9 
levels were also elevated in the normal liver tissues in 
anti-VEGFR-2ScFv-As2O3-stealth nanoparticle group, the 
difference was not statistically significant (P>0.05), and the 
elevated caspase-3,-9 levels might due to the small amount 
of free As2O3 nanoparticle in the anti-VEGFR-2ScFv-
As2O3-stealth nanoparticle conjugate. And in As2O3 stealth 
nanoparticle and As2O3 group the apoptotic protein caspase-
3,-9 in liver tissue were both increased in a statistically 
significant level (P<0.05, Figure 5C).
A
B
C
Caspase-3
Caspase-9
毬-actin
Caspase-3
Caspase-9
毬-actin
Tumor tissues
Normal tissues
Figure 5. Apoptosis of tumor cells.
(A) H&E staining showed necrosis condition inside the tumor tissues. 
(B) TUNEL assay showed the cell apoptosis in the tissues. (C) 
Apoptotic protein expression detected by western blot showed that the 
drugs mainly affect the expression of caspase-3, -9, and almost had 
no effect on normal cells.
 A. Anti-VEGFR-2 ScFv-As2O3 stealth nanoparticles group; B, 
As2O3 stealth nanoparticles group; C. anti-VEGFR-2 ScFv; D, As2O3 
solution group; E. saline (Control).
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3.6. Microvascular density
  The count of MVD in tumor tissues from anti-VEGFR-2 
ScFv-As2O3, stealth nanoparticles group (5.5依1.8), As2O3 
stealth nanoparticles group (7.6依1.5), anti-VEGFR-2 ScFv 
(6.8依1.2), and As2O3 solution-treated mice (8.7依0.7) was 
significantly decreased (P<0.001) compared with those from 
control mice (12.4依2.3). MVD of anti-VEGFR-2 ScFv-As2O3 
stealth nanoparticles and anti-VEGFR-2 ScFv group were 
relatively smaller than the other two groups, indicating that 
the anti-VEGFR2ScFv antibody significantly improve the 
anti-angiogenesis effects of As2O3. 
4. Discussion
  Hepatocellular carcinoma is the most common type of liver 
cancer. Treatment options of HCC patients and prognosis 
in clinical are dependent on many factors but especially 
on tumor size and staging of the patients. Once diagnosed 
hepatocellular carcinoma usually have a poor prognosis in 
the late stage, only 30%-40% of patients are deemed eligible 
for curative intention with traditional treatment modalities 
including surgical resection, liver transplantation, 
chemoembolization and radiotherapy[20]. And there is not 
sufficient choice of chemotherapy drugs for the treatment 
of hepatocellular carcinoma, so new drug design and 
development for efficient drugs for HCC need to be paid 
more attention to in this field.
  Invasion and metastasis are the most insidious and life-
threatening aspects of almost all malignant cancers. Cancer 
invasion is initiated and maintained by several signaling 
pathways that control cytoskeletal dynamics and the 
turnover of cell-matrix and cell-cell junctions, followed by 
cell migration into the adjacent tissues[21]. Cancer related 
angiogenesis is a prerequisite for the local expansion of 
tumor colonies beyond the size restricted by oxygen and 
nutrient diffusion. Angiogenesis is related to increased 
metastasis formation and decreased overall survival in 
patients with various malignant tumors. VEGF is one of the 
key regulators of angiogenesis process[22]. VEGF-targeting 
therapies have so far shown significant benefits and been 
successfully integrated in routine clinical practice for 
several types of cancer[23]. In our study, Transwell assay 
showed that when VEGFR-2 was blocked by drugs, the 
invasion ability of cancer cells was significantly decreased, 
indicating that the choice of anti-VEGFR-2 as the target 
was a good strategy for the drug design.
  As2O3 is the inorganic compound with the formula As2O3, 
which is also an environmental toxicant as well as an 
effective anti-cancer agent against many types of cancers 
that can produce severe side effects, such as cardiac toxicity, 
peripheral neuritis, gastrointestinal adverse reactions, 
liver, kidney failure and respiratory paralysis and even 
death, thus the therapeutic use of As2O3 has been limited 
by its dose-dependent toxicity. The reasonable application 
of arsenic trioxide can not only avoid toxicity, but also 
have good effects for a number of incurable diseases. In 
recent years, along with clinical research, there was a good 
effect in some surgical syndrome, but particularly show a 
good development prospects in the treatment of malignant 
tumors[24-26].
  Anti-tumor effect of As2O3 has been confirmed these years 
with the development of in vitro studies, animal model, 
clinical trials and other aspects, and different formulations 
have also been studied in order to reduce its toxic side 
effects, which also become a hot research field in recent 
years. Previous studies have confirmed that As2O3 could 
induce apoptosis of hepatoma cells and also inhibit the 
growth of hepatocellular carcinoma grown in nude mice[27]. 
However, the toxic side effects of arsenic are still worthy to 
be paid more attention to, which is prone to poisoning and 
lead to serious consequences. Antibody Drug Conjugates or 
ADCs are a new class of highly potent biopharmaceutical 
drugs designed as a Targeted therapy for the treatment of 
people with cancer. In design of antibody-drug conjugates, 
a anticancer drug such as cell toxin or cytotoxin is coupled 
to an antibody that specifically targets a certain tumor 
marker[28]. In this study we chose the nano-particles As2O3 
to couple with the targeting antibody anti-VEGFR-2 ScFv. 
For liver cancer cell line, As2O3 was highly cytotoxic, and 
the effect of the same concentration of As2O3 nanoparticles 
is more obvious which was also confirmed in our study. The 
use of anti-VEGFR-2 ScFv-As2O3 stealth nanoparticles 
could significantly enhance the therapeutic effects while 
reducing the toxical side effects of As2O3.
  In summary, our results showed that anti-VEGFR-2 ScFv-
As2O3 stealth nanoparticles could improve bioavailability, 
reduce drug dosage, side effects and improve efficacy when 
used for treatment of hepatoma cancer both in vitro and in 
vivo.
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